Hong-Fen Guo

Department of Pediatrics, Memorial Sloan Kettering Cancer Center

Affiliated withMemorial Sloan Kettering Cancer Center

Research Area

Biography

Hong-Fen Guo has not added Biography.
If you are Hong-Fen Guo and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2023

Other Publications

Article	Year
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. The Journal of experimental medicine\| PubMed ID: 9705944	1998
Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. Hybridoma and hybridomics\| PubMed ID: 12573107	2002
Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybridoma and hybridomics\| PubMed ID: 14511566	2003
Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia (New York, N.Y.)\| PubMed ID: 15720811	2004
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer biotherapy & radiopharmaceuticals\| PubMed ID: 16248769	2005
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer research\| PubMed ID: 19584290	2009
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Molecular cancer therapeutics\| PubMed ID: 20371725	2010
In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PloS one\| PubMed ID: 23696816	2013
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Molecular cancer therapeutics\| PubMed ID: 24944121	2014
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. The Journal of biological chemistry\| PubMed ID: 25851904	2015
A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem cell research\| PubMed ID: 26342562	2015
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. The Journal of biological chemistry\| PubMed ID: 26487718	2015
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European journal of nuclear medicine and molecular imaging\| PubMed ID: 26596724	2016
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 28705917	2017
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Molecular cancer therapeutics\| PubMed ID: 30082472	2018
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics\| PubMed ID: 30429889	2018
An -Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate chemistry\| PubMed ID: 31891487	2020
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Science translational medicine\| PubMed ID: 32161106	2020
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 32958698	2021
Alpha radioimmunotherapy using Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics\| PubMed ID: 33052220	2020
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies. Journal for immunotherapy of cancer\| PubMed ID: 33239418	2020
Potent antitumor effect of T cells armed with anti-GD2 bispecific antibody. Pediatric blood & cancer\| PubMed ID: 33844437	2021
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. Journal for immunotherapy of cancer\| PubMed ID: 34035113	2021
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. Journal for immunotherapy of cancer\| PubMed ID: 34497115	2021
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular cancer therapeutics\| PubMed ID: 34667111	2022
Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. Journal for immunotherapy of cancer\| PubMed ID: 36990507	2023
Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors. Frontiers in oncology\| PubMed ID: 37091153	2023